Pfaff, Gill & Ports, Ltd. is prosecuting a case against a Chicago-area doctor who continued to prescribe Reglan (metoclopramide) to a patient for more than four years. Unfortunately, our client developed tardive dyskinesia and dystonia due to the prolonged Reglan use, which has totally disabled him from working and his family’s everyday life. The doctor failed to inform our client that the drug should not be taken for more than 12 weeks and that doing so results in a significant risk of tardive dyskinesia, a disabling movement disorder.
In 2009, the FDA required the manufacturer to issue a black box warning against administering Reglan for more than 12 weeks except in rare cases. The prescribing doctor was unfamiliar with that warning and prescribed the medication to treat a presumed diagnosis of gastroparesis from 2010 until August 2014 when our client’s symptoms were recognized to be tardive dyskinesia. Reglan, the brand name, is manufactured by Wyeth, and its generic versions are manufactured by Actavis and Teva.
